CLINICAL TRIALS PROFILE FOR PRADAXA
✉ Email this page to a colleague
All Clinical Trials for pradaxa
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01153698 ↗ | Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery | Terminated | Boehringer Ingelheim | 2010-08-01 | an open, prospective, observational study to collect data on safety (major bleeding events) and efficacy (symptomatic venous thromboembolism(VTE)) of a switch from Enoxaparin to dabigatran etexilate in patients with total knee replacement (TKR) and total hip replacement (THR) | |
| NCT01184989 ↗ | Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate | Completed | Boehringer Ingelheim | Phase 4 | 2010-08-01 | To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip- or knee-replacement surgery, this PK/PD study will be conducted. |
| NCT01210755 ↗ | Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics | Completed | University Hospital, Grenoble | Phase 4 | 2010-11-01 | The purpose of this study is to evaluate whether the effect of the two new anticoagulants, Dabigatran and Rivaroxaban, can be reversed by non-specific and specific inhibitors. For Dabigatran the investigators will test the non-specific inhibitors: prothrombin complex concentrate (PCC), recombinant activated coagulation factor VII, and activated prothrombin-complex (FEIBA). For Rivaroxaban the investigators will test a specific Rivaroxaban decoy (FXa-GLAless). This will be done in a laboratory using blood plasma from healthy male volunteers. |
| NCT01241539 ↗ | Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis | Completed | Boehringer Ingelheim | Phase 1 | 2010-11-01 | The current study will allow the assessment of pharmacokinetics, pharmacodynamics, elimination rate and clearance of dabigatran etexilate during and following haemodialysis in ESRD patients. |
| NCT01339819 ↗ | Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation | Completed | Deutsches Herzzentrum Muenchen | Phase 4 | 2011-04-01 | The aim of this study is to evaluate whether Dabigatran itself reduces ADP induced platelet aggregation measured by MEA as compared to Phenprocoumon after a two-week treatment with either agent. |
| NCT01352702 ↗ | Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation | Terminated | Deutsches Herzzentrum Muenchen | Phase 4 | 2011-05-01 | The aim of this study is to evaluate whether dabigatran reduces clopidogrel mediated ADP induced platelet aggregation measured by MEA as compared to phenprocoumon after a two-week treatment with either agent. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pradaxa
Condition Name
Clinical Trial Locations for pradaxa
Trials by Country
Clinical Trial Progress for pradaxa
Clinical Trial Phase
Clinical Trial Sponsors for pradaxa
Sponsor Name
